canadian association of gastroenterology clinical practice guidelines: the use of tumour necrosis factor-alpha antagonist therapy in crohn’s disease
Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文

canadian association of gastroenterology clinical practice guidelines: the use of tumour necrosis factor-alpha antagonist therapy in crohn’s disease

;Daniel C Sadowski;Charles N Bernstein;Alain Bitton;Ken Croitoru;Richard N Fedorak;Anne Griffiths;the CAG Crohn’s Consensus Group
indian journal of pharmacology 2009 Vol. 23 pp. 185-202
199
sadowski2009canadiancanadian

Abstract

BACKGROUND: Guidelines regarding the use of infliximab in Crohn’s disease were previously published by the Canadian Association of Gastroenterology in 2004. However, recent clinical findings and drug developments warrant a review and update of these guidelines.

Keywords

Gastroenterology diseases of the digestive system

Access

DOI:
10.1155/2009/201430
URL:
http://dx.doi.org/10.1155/2009/201430

Citation

ID: 229119
Ref Key: sadowski2009canadiancanadian
Use this key to autocite in SciMatic or Thesis Manager

References

References

No Bibliography

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
229119
Unique Identifier:
10.1155/2009/201430
Network:
Scimatic Chain (ID: 481)
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet
Gas fees required in SCI Coins
Buy SCI

Saymatik Web3.0 Wallet

Google Play
App Store